These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20644468)

  • 21. Pathogenesis and management of the dyslipidemia of the metabolic syndrome.
    Raal FJ
    Metab Syndr Relat Disord; 2009 Apr; 7(2):83-8. PubMed ID: 19400742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk.
    Ginsberg HN; Stalenhoef AF
    J Cardiovasc Risk; 2003 Apr; 10(2):121-8. PubMed ID: 12668909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What is the most effective strategy for managing diabetic dyslipidaemia?
    Reasner CA
    Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
    Polis AB; Abate N; Catapano AL; Ballantyne CM; Davidson MH; Smugar SS; Tershakovec AM
    Metab Syndr Relat Disord; 2009 Dec; 7(6):601-10. PubMed ID: 19929597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
    Sampalis JS; Bissonnette S; Habib R; Boukas S;
    Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
    Deedwania PC; Hunninghake DB; Bays HE; Jones PH; Cain VA; Blasetto JW;
    Am J Cardiol; 2005 Feb; 95(3):360-6. PubMed ID: 15670545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination therapy for the treatment of dyslipidemia.
    Streja D
    Curr Opin Investig Drugs; 2004 Mar; 5(3):306-12. PubMed ID: 15083597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of atherogenic dyslipidemia of the metabolic syndrome: evolving rationale for combined drug therapy.
    Vega GL
    Endocrinol Metab Clin North Am; 2004 Sep; 33(3):525-44, vi. PubMed ID: 15262295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trials of cardiovascular risk factor management in type 2 diabetes.
    Patel A; Joshi R; de Galan B
    Curr Opin Cardiol; 2009 Jul; 24(4):288-94. PubMed ID: 19322080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).
    Everett BM; Glynn RJ; MacFadyen JG; Ridker PM
    Circulation; 2010 Jan; 121(1):143-50. PubMed ID: 20026779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia.
    Wierzbicki AS
    Curr Opin Cardiol; 2009 Jul; 24(4):372-9. PubMed ID: 19424060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonpharmacologic management of mixed dyslipidemia associated with diabetes mellitus and the metabolic syndrome: a review of the evidence.
    Stone NJ
    Am J Cardiol; 2008 Dec; 102(12A):14L-18L. PubMed ID: 19084085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interpreting clinical trials of diabetic dyslipidaemia: new insights.
    Wierzbicki AS
    Diabetes Obes Metab; 2009 Mar; 11(3):261-70. PubMed ID: 17645560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How to reach LDL targets quickly in patients with diabetes or metabolic syndrome.
    Leiter LA; Martineau P; de Teresa E; Farsang C; Gaw A; Gensini G; Langer A;
    J Fam Pract; 2008 Oct; 57(10):661-8. PubMed ID: 18842192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular risk: prevention and treatment of the metabolic syndrome.
    Tuomilehto J
    Diabetes Res Clin Pract; 2005 Jun; 68 Suppl 2():S28-35. PubMed ID: 15953504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
    Yamagishi S; Matsui T; Sato T; Takeuchi M
    Med Hypotheses; 2006; 66(3):609-11. PubMed ID: 16171951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
    Davidson MH
    Expert Opin Drug Saf; 2006 Jan; 5(1):145-56. PubMed ID: 16370963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of dyslipidemia in patients with complicated metabolic syndrome.
    Davidson MH
    Am J Cardiol; 2005 Aug; 96(4A):22E-25E. PubMed ID: 16098839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.